Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study
โ Scribed by B. Hoogstraten; S. L. George; B. Samal; S. E. Rivkin; J. J. Costanzi; J. D. Bonnet; T. Thigpen; H. Braine
- Publisher
- John Wiley and Sons
- Year
- 1976
- Tongue
- English
- Weight
- 595 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c
## Abstract Eighteen (72%) of 25 evaluable and previously untreated patients with adult acute lymphoblastic leukemia entered complete remission (CR) following induction therapy with Adriamycin, vincristine, and prednisone in a Southwest Oncology Group study. Remission maintenance therapy with metho
Background. Extragonadal germ cell tumors (EGGCT) are uncommon, occur primarily in the mediastinum and retroperitoneum, and have been noted to have variable response rates to cisplatin-based chemotherapy regimens. Methods. The Southwest Oncology Group (SWOG) has completed a prospective trial of com